Angiotensin II mediates its effects through angiotensin receptors. The use of specific angiotensin receptor ligands and the cloning of these receptors allows their classification. So far, the AT 1 , AT 2 and atypical angiotensin II receptors are recognised. The AT 1 receptor is responsible for the classical effects of the renin-angiotensin system such as vasoconstriction, renal salt and
Introduction
Angiotensin II (Ang II), the effector peptide of the renin-angiotensin system (RAS), exerts a multitude of actions. It is an eight amino acid molecule and is produced in the circulation and also in tissues. 1, 2 Besides being the classically recognised potent vasoconstrictor, it is involved in cell growth, hormone secretion and neuronal activities. The latter two processes, which include arginine vasopressin (AVP), adrenocorticotrophic hormone or oxytocin release, the centrally-induced drinking response and modulation of the sympathetic outflow to the periphery, reflect the general purpose of the RAS, which is to maintain water and electrolyte balance and organ perfusion. 3, 4 In recent years it has become more evident that the RAS plays a major role in the development and maintenance of arterial hypertension. Ang II has also been implicated in cardiovascular and renal pathology, such as cardiac left ventricular hypertrophy, neointima formation, post infarct remodelling and nephrosclerosis. [4] [5] [6] Ang II is capable of inducing cell proliferation and is as such probably contributing under pathological conditions to structural alterations in various organs. [6] [7] [8] Ang II mediates its actions through a set of angiotensin receptors (Table  1) . 9 In the past, both the short and long-term effects of Ang II were thought to be mediated by a single receptor. However, the development of selective angiotensin receptor ligands and cloning efforts allowed the classification of angiotensin receptors. Generally recognised are the AT 1 and AT 2 receptors. [9] [10] [11] The AT 1 receptor exists as two isoforms, namely the AT 1 a and the AT 1 b receptor. 11 The AT 1 receptors are involved in blood pressure regulation, the drinking response and cell proliferation. The AT 1 receptor can be efficiently blocked by the family of the so-called 'sartan' compounds: the earliest being losartan, followed by valsartan, eprosartan, irbesartan, candesartan, and telmisartan. 12 The function of the AT 2 receptor is a matter of debate, but recent studies show it to be involved in antiproliferative effects, programmed cell death and neuronal differentiation. 
Cloned angiotensin receptors
Angiotensin receptor sequence information in combination with Southern blot data allows the classification of three major angiotensin receptor subtypes, namely the AT 1 a, AT 1 b and the AT 2 receptor. Both AT 1 a and AT 1 b receptors have been identified in rats, mice and xenopus. [16] [17] [18] [19] [20] In rats, the AT 1 a receptor gene is located on chromosome 17, and AT 1 b is located on chromosome 2. Although sequence information is available from humans, which suggests the existence of a second AT 1 receptor, [21] [22] [23] only a single AT 1 gene was detected on chromosome 3. Sequence information obtained after polymerase chain reaction (PCR) cloning suggests the existence of a third AT 1 (AT 1 c) subtype in the rat. 24 Like the putative AT 1 receptor subtype in humans, no chromosomal localization has been identified for the rat AT 1 receptor subtype.
AT 1 receptor cDNA has been obtained from a number of tissues, such as heart, liver, and placenta. The majority of the open reading frames encode for 359 amino acid receptors. The AT 1 a and AT 1 b subtypes are highly homologous. In the rat and mouse, they exhibit a 91% similarity on nucleic acid and a 96% similarity on amino acid level. The human AT 1 and rat AT 1 a receptor nucleic acid and amino acid sequences share an 86% and 94% homology respectively. The differences are not located in a particular region of the receptor but are evenly spread throughout the coding region.
The rat AT 1 a gene has a size of at least 84 kilo bases (kb) and is composed of four exons. [25] [26] [27] The entire coding sequence is located in its last exon. The AT 1 b gene is at least 15 kb long and exists of three exons and encodes transcripts of approximately 2.4 kb in size. 28 Its coding region is located entirely in the third exon. The single human AT 1 receptor gene has a minimum size of 60 kb and contains five exons, with the entire coding region within the fifth exon. [29] [30] [31] The AT 2 receptor has been cloned from mouse, rat and human. [32] [33] [34] [35] [36] [37] In all three species the AT 2 receptor cDNA encodes for a 363 amino acid receptor, and sequence comparison reveals an expectedly high homology on both the nucleic and amino acid level (human and rat AT 2 receptor cDNA share a homology of 89% and 91% on nucleic acid and amino acid level, respectively). Both, mouse and human AT 2 receptor genes are located on the X chromosome. 38, 39 The human AT 2 receptor gene consists of three exons with its entire coding region located in the third exon. 37, 40 The AT 2 receptor cDNA has been isolated from a number of tissues and from whole rat and mouse fetuses. Comparing the AT 1 -and AT 2 nucleic acid sequences reveals a lack of homology (only a 34% identity). 41 suggest the existence of an additional AT 2 receptor. They showed that the mouse neuroblastoma cell line N1E-115 possesses two distinct AT 2 receptor populations. These two receptor types differ in their affinity for PD123319, and appear to be immunologically distinct proteins. However, no AT 2 receptor subtype has been cloned from this particular cell line yet.
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Atypical angiotensin receptors
The use of the specific angiotensin receptor ligands, such as the AT 1 receptor antagonist, losartan, the AT 2 receptor agonist, CGP 42112A, and the AT 2 receptor antagonists, PD 123177 and PD 123319, has led to the identification of atypical angiotensin receptor sites which reveal binding properties not characteristic for the AT 1 or the AT 2 receptor. Bovine adrenal membranes contain a binding site which has been called the AT 4 receptor since it has a high affinity for the hexapeptide Angiotensin IV (3-8 Angiotensin). 42 It has a low affinity for Ang II, and neither losartan nor CGP 42112A, nor PD 123177 are able to compete for this site using accepted pharmacological concentrations. Angiotensin IV is capable of eliciting biological responses in vitro. In bovine coronary venular endothelial cells and in rabbit cardiac fibroblasts it has been reported to stimulate nucleic acid synthesis. 43, 44 The AT 4 receptor is also expressed in the guinea pig and rat brain. Fos-like immunoreactivity was detected in the hippocampus and the piriform cortex after Angiotensin IV intracerebroventricular injection. This effect was insensitive to pretreatment with losartan or PD 123177. 45 An atypical angiotensin binding site exists in cell cultures containing more than 95% human cardiac fibroblasts. 46 Angiotensin (1-7) Ͼ Ang II Ͼ Angiotensin IV competed for the binding site, whereas losartan and PD 123319 were unable to compete with the agonists. Ang II stimulates these cells to proliferate, which cannot be blocked by losartan and PD 123319. A receptor with comparable binding properties has also been detected in the human uterus. 47 Human keratinocytes in culture also proliferate in response to Ang II. This effect maybe mediated through an atypical angiotensin receptor as well, since losartan and PD were not able to compete with angiotensin for its binding site. 48 Besides eliciting its action through cell surface receptors, Ang II might mediate its actions through intracellular located receptors, since Ang II binding to hepatocyte nuclei has been shown to increase overall RNA transcription and specific renin and angiotensinogen RNA synthesis. 49 Additional reports describe the presence of atypical angiotensin receptors on a rat epithelial cell 50 line, on chicken liver membranes, 51 on chick sympathetic neurons 52 and on a strain of mycoplasma hyorhinis, isolated from opossum kidney cells.
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AT 1 receptor and signal transduction
Translation of the open reading frame of the AT 1 receptor predicts it to be a G-protein-coupled recep-tor and it was subsequently found that its signalling is dependent on phospholipases C (PLC), D, and A2 activation. PLC activation leads to the hydrolysis of phosphatidylinositol 4,5-biphosphate (PIP 2 ) to 1,4,5-IP 3 and diacylglycerol (DAG), which in turn leads to intracellular calcium mobilisation and the stimulation of protein kinase C. 54 The rise in intracellular calcium is associated with typical AT 1 receptor associated responses such as vasoconstriction and secretion of aldosterone. The cascade induced by PLD and PLA 2 leads to the formation of fatty acids. PLD hydrolyses phosphatidylcholine (PC) into phosphatidic acid (PA) and choline. PA and DAG can be inter-converted allowing the degradation of the latter to fatty acids and glycerol by DAG lipase. PLA 2 hydrolyses PC and phosphatidylethanolamine (PE) into the corresponding lysophospholipids (LPC, LPE) and fatty acids. A fatty acid frequently released by PLA 2 and DG lipase is arachidonic acid, which is a precursor of leukotrienes and prostaglandins.
The PLC exists in several isoforms which can be subdivided in three classes, namely PLC-␤, PLC-␥ and PLC-␦. 55 The four ␤-isoforms are thought to be activated by subunits of G-proteins, whereas the ␥ isoforms have to be activated by tyrosine phosphorylation. AT 1 receptor activation leads to the tyrosine phosphorylation of PLC-␥1 in both rat smooth muscle and glomerular mesangial cells. 56, 57 In smooth muscle cells it has been shown that for this purpose the AT 1 receptor has to recruit the soluble tyrosine kinase pp60 c-src , since the receptor itself lacks intrinsic kinase activity. 58 PLC-␥1 phosphorylation leads to the PIP 2 hydrolysis into 1,4,5-IP 3 and DAG. 1,4,5-IP 3 induction leads to intracellular calcium release which in turn induces smooth muscle cell contraction and other signalling events.
Recent reports link Ang II, through the AT 1 receptor, to the Jak/STAT signalling pathway. 59, 60 This is a significant observation since the Jak/STAT pathway has been previously identified for cytokine receptors which leads to transcriptional activation of early growth-response genes, 61 and is now possibly also an important signalling pathway through which Ang II mediates its proliferative effects. 62 Generally, in response to ligand binding, Jak kinases associate with dimerized cytokine receptors, autophosphorylate, and activate signalling molecules via tyrosine phosphorylation, which in turn leads to association of the Jak substrates STAT1 and STAT2 and p48. 63 These associated proteins form the ISGF3 complex which translocates to the nucleus, where it binds to specific DNA elements resulting in the transcription of early growth response genes, such as c-fos. Similar to cytokine receptors, activation of AT 1 receptors leads to c-fos induction, probably leading to cell proliferation. 62 Interaction of Ang II with the Jak/STAT pathway has been observed in rat aortic smooth muscle cells. 60 Ang II is able to rapidly phosphorylate tyrosine of the kinases Jak2 and Tyk2. Stimulation of Jak activity also leads to the phosphorylation of both STAT1 and STAT2 proteins and subsequent translocation to the nucleus of the STAT1 protein. In cultured neonatal fibroblasts, Bath et al 59 showed that Ang II induces STAT protein phosphorylation and translocation of STAT proteins, leading to initiation of gene transcription. In neonatal rat cardiac myocytes cells, STAT1 and STAT3 are rapidly phosphorylated in response to Ang II, and co-immunoprecipitation experiments have shown that the AT 1 receptor is directly linked to components of the Jak/STAT pathway. 64 Also, antibodies against STAT proteins in vascular smooth muscle cells inhibit the Ang II mediated proliferative response. 65 A physical association between Jak2 kinase and a part of the intracellular carboxy tail of the AT 1 receptor has been shown as well. 66 Very recently it has been shown that Ang II mediates the Jak/STAT pathway under pathological conditions as well.
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AT 2 receptor and signal transduction
Before the AT 2 was cloned, numerous studies had been performed on a number of cell types to determine AT 2 receptor signalling mechanisms. These studies revealed that Ang II through the AT 2 receptor regulates ionic currents, decreases cyclic guanosine monophosphate (GMP) levels, and stimulates the production of arachidonic acid. 68 Bottari and coworkers demonstrated that Ang II decreases cyclic GMP levels in the pheochromocytoma cell line PC12W 69 and Sumners et al 70 has shown that a similar effect by Ang II on neonatal neuronal cultures was inhibited by PD123177 and CGP42112A, but not by losartan.
The decrease of cyclic GMP appears to be caused by a stimulation of a protein tyrosine phosphatase, followed by an inhibition of a membrane-bound particulate guanylate cyclase. In contrast, AT 2 receptormediated inhibition of protein tyrosine phosphatase has been reported in PC12W cells, in rat fetal skin and COS-7 cells permanently transfected with AT 2 cDNA. 68, 71 In vivo experiments have also shown that the AT 2 receptor is able to mediate cGMP levels. 72 Co-infusion experiments on spontaneously hypertensive rats, revealed that Ang II increases aortic cyclic GMP levels through the AT 2 receptor, an effect which could be prevented by PD 123319 infusion.
It has been shown that Ang II through the AT 2 receptor mediates potassium currents in neonate rat neurons co-cultured from hypothalamus and brain stem. 73 AT 2 receptor stimulation of potassium currents could be abolished by pertussis toxin and by an antibody against the inhibitory GTP binding protein. The Ang II effect was also inhibited by the serin/threonine phosphatase inhibitor okadaic acid and by antibodies against serine/threonine phosphatase 2A. 74 To make sure that these mechanisms are mediated through the known AT 2 receptor instead of an unknown Ang II docking site, Kang et al 75 injected into cultured neurons a 22 amino acid peptide corresponding to the putative third intracellular loop of the cloned AT 2 receptor. This injection caused an increase in potassium current similar to the effect produced by Ang II, a reaction which was abolished by pertussis toxin and inhibited by okadaic acid.
Signal transduction data have also been obtained from the murine neuroblastoma cell line N1E-115. This cell line exclusively expresses AT 2 receptors, and incubation with Ang II or CGP 42112 leads to a decrease in tyrosine phosphorylation of a number of proteins. 76 This effect is abolished in the presence of AT 2 receptor antagonists. The involvement of the AT 2 receptor in tyrosine phosphorylation events suggest a role for this receptor in growth and differentiation processes, since they are known to involve cascades of tyrosine phosphatases and kinases. Results on N1E-115 cells show that AT 2 receptors inhibit the activity of mitogen-activated protein (MAP) kinases which are induced by serum or epidermal growth factor. 77 MAP kinases are targets of growth factors and once activated they are involved in cell development and differentiation. Additional evidence for a link of the AT 2 receptor and MAP kinase activity has been obtained from R3T3, PC12W and neuronal cells. 78, 79 In these cell types, AT 2 receptor stimulation results in a decrease in MAP kinase activity. The antiproliferative character of the AT 2 receptor is reflected in the inhibition of MAP kinase activity. However, additional data show that this characteristic is not reflected on c-fos and c-jun immediate early gene level. In PC12W cells, cfos and c-jun mRNA expressions are not inhibited through the AT 2 receptor.
80
The function of the AT 2 receptor Data obtained from signal transduction studies support the notion that the AT 2 receptor plays a role in growth and differentiation processes, and additional studies describe such a role for this receptor. For instance, our research group has demonstrated that Ang II is antiproliferative for coronary endothelial cells (CEC), 81 and that growth stimulation of CEC by bFGF can be inhibited by AT 2 receptor activation. 13 Under AT 2 receptor blockade these cells proliferated, and losartan pretreatment abolished this effect.
Similar data have been obtained by van Kersteren et al 82 using neonatal rat cardiomyocytes and fibroblasts. Ang II in the presence of PD 123319, increased total protein levels and induced [ 3 H]leucine and [ 3 H]thymidine incorporation under growth conditions of these cells. Growth inhibition by the AT 2 receptor has been observed in vivo as well. In vivo gene transfer of the AT 2 receptor cDNA into injured carotid artery resulted in an attenuation of neointimal hyperplasia. 83 The results obtained from CEC have been extended by our research group to the PC12W cell line as well.
14 In these cells, which exclusively express AT 2 receptors, Ang II inhibited fetal calf serum-and epidermal growth factor-induced cell proliferation. Additional data obtained from PC12W cells show not only a role for the AT 2 receptor in growth but also on differentiation. 14 The stimulation of PC12W cells with nerve growth factor (NGF), a polypeptide hormone that is involved in development and maintenance of the sympathetic sensory and central nervous system (CNS) is extensively used as a model system for neuronal differentiation. These cells show short and long term responses to NGF. The long term responses can be summarised as a morphological differentiation of the cells from immature neuroblasts to a form in which they resemble mature sympathetic neurons. We have observed that daily treatment of these cells with Ang II resulted in differentiation and that Ang II treatment enhanced low-dose NGF-induced neurite formation, which was inhibited in the presence of PD 123177. 14 The molecular events leading to morphological differentiation in PC12W after AT 2 receptor stimulation are unknown. In these cells, investigation revealed a differential regulation of microtubulecomponents such as ␤-tubulin, the microtubule associated proteins MAP1B and MAP2 and also of the middle-sized neurofilament (NF-M). 15, 84 Ang II is capable of enhancing the protein levels of ␤-tubulin and MAP2, whereas NGF enhanced the protein levels of all four proteins. In contrast, MAP1B protein levels were decreased in both quiescent cells and in NGF co-stimulated cells. Also, on mRNA levels as well, Ang II counteracted NGF-mediated NF-M up-regulation and reduced dramatically NF-M levels in the absence of NGF. The ANG II-induced effects were completely abolished by the pretreatment with PD 123177. 15, 85 These observations imply that NGF-and Ang II-induced differentiation processes follow distinct cellular pathways. Similar effects have been observed in the neuronal cell line NG108-15 as well. 86 In these cells, tubulin and MAP2C levels are increased in response to Ang II, an effect which is completely abolished in the presence of PD 123319.
Both angiotensin receptor subtypes have also been connected to the regulation of several extracellular matrix proteins, such as fibronectin, thrombospondin and tenascin in CEC. 87 The fact that the expression of AT 2 receptor takes place within a distinct time frame during embryonic development (completely reversed in certain areas of the CNS in the adult) and induced expression in wound healing processes and cardiac remodelling, clearly suggests a role for the AT 2 receptor in differentiation and development. 88, 89 In R3T3 cells, Ang II was able to inhibit bFGF stimulated cell proliferation. 90 R3T3 cells, which, of the known angiotensin binding sites, exclusively express the AT 2 receptors, are mouse embryonic fibroblasts derived from the Swiss 3T3 cell strain. Experimental results obtained from these cells might be representative of AT 2 receptor function in fetal development, since one of the sources of abundant AT 2 receptor expression in fetal mesenchymal tissue is undifferentiated fibroblasts. 88 The function of the AT 2 receptor in R3T3 cells is not known. However, binding assays have shown that the number of cell surface AT 2 receptors increases dramatically when R3T3 cells are contact-inhibited and that stimulation with various mitogens causes a rapid decline of cell surface AT 2 receptors. [91] [92] [93] [94] Very recently, Goto et al 95 have shown that the AT 2 receptor is abundantly expressed upon confluency of primary mesangial cell cultures from normotensive WistarKyoto (WKY) rats as well. In contrast, analysis of mesangial cells from stroke-prone hypertensive rats, which have a higher proliferative activity as compared to those from WKY rats, revealed no AT 2 receptor expression. The expression pattern of the AT 2 receptor in R3T3 and mesangial cells, and the previously mentioned expression pattern during embryonic development in the light of the origin of R3T3 cells, might be indicative for a role of the AT 2 receptor on growth and development.
Ultimately, AT 2 receptor activation might lead to programmed cell death or apoptosis in PC12W cells. 79 Apoptosis in response to Ang II through the AT 2 receptor has been reported for R3T3 cells 79, 96 and for rat ovarian granulosa cells as well. 97 In the latter cell type the AT 2 binding sites are increased under apoptotic conditions. Withholding folliclestimulating hormone (FSH) causes internucleosomal fragmentation, which is characteristic for apoptosis, and induces AT 2 binding activity. Ang II enhances AT 2 binding activity under FSH-free conditions, which can be blocked by PD 123319. Ang II is also capable of inducing the AT 2 binding site on R3T3 cells. 91 What is interesting is that not only Ang II but a number of AT 2 receptor ligands, including antagonists, are capable of up-regulating the receptor.
Several reports also indicate a role for the AT 2 receptor in blood pressure regulation. Ang II causes an enhanced depressor response in rats when AT 1 receptors are blocked. This effect is blocked by PD 123177. 98 Also, co-infusion of rats with Ang II and PD 123199 results in an enhanced blood pressure response as compared to rats infused with Ang II alone. 99 Although the AT 2 receptor seems to be involved in growth and differentiation, lack of a functional receptor still allows for development of an organism as illustrated by the establishment of AT 2 knockout mice strains. Data obtained from these mice link the AT 2 receptor to behaviour and to altered blood pressure regulation as well.
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Summary
The AT 1 receptor antagonists are already used in anti-hypertension treatment. Whether these compounds will be as successful as the angiotensinconverting enzyme (ACE) inhibitors in the treatment of cardiovascular diseases remains open. Targeting the RAS on receptor level allows a more specific treatment of cardiovascular diseases compared to the use of ACE inhibitors, however it is not clear if this is also more beneficial. Additionally, the recognition of a role for the AT 2 receptor in cellular growth and neuronal differentiation allows for relevant questions regarding treatment with AT 1 receptor antagonists. One of these questions in relation to the AT 2 receptor might be: what effect has the expected increase of Ang II levels due to the negative feedback mechanism by blocked AT 1 receptors on the unopposed AT 2 receptor? Extensive research on AT 2 receptor-mediated processes and of the regulation of the AT 2 receptor itself is of major importance when trying to understand the complexity of the RAS system especially in relationship with therapy of cardiovascular disease, since interference with AT 2 receptor-mediated processes might have a direct effect on AT 2 receptor-mediated events.
